Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

Conference Coverage
Impact of Biosimilar Substitution on Provider Risk in Value-Based Oncology Payment Models
06/14/2022

Ellen Kurek

Ellen Kurek
Researchers at the 2022 ASCO Annual Meeting estimated the impact of biosimilar substitution on financial risk to providers in oncology value-based payments by applying simulation approaches to model the episode framing, pricing, and risk...
Researchers at the 2022 ASCO Annual Meeting estimated the impact of biosimilar substitution on financial risk to providers in oncology value-based payments by applying simulation approaches to model the episode framing, pricing, and risk...
Researchers at the 2022 ASCO...
06/14/2022
Journal of Clinical Pathways
Conference Coverage
Examining the Prevalence of Prior Authorizations for Use of PARP Inhibitors in Ovarian Cancer
06/14/2022

Ellen Kurek

Ellen Kurek
Researchers at the 2022 ASCO Annual Meeting examined the prevalence of prior authorization for PARP inhibitors among patients with ovarian cancer overall, by frontline or recurrent maintenance, and by genetic status.
Researchers at the 2022 ASCO Annual Meeting examined the prevalence of prior authorization for PARP inhibitors among patients with ovarian cancer overall, by frontline or recurrent maintenance, and by genetic status.
Researchers at the 2022 ASCO...
06/14/2022
Journal of Clinical Pathways
Conference Coverage
Exploring Real-World Data on the Efficacy and Safety of Oncology Drugs
06/14/2022

Ellen Kurek

Ellen Kurek
A study presented at the ASCO Annual Meeting aimed to establish a data collection framework of EMR-based real-world data to evaluate the effectiveness and safety of cancer drugs.
A study presented at the ASCO Annual Meeting aimed to establish a data collection framework of EMR-based real-world data to evaluate the effectiveness and safety of cancer drugs.
A study presented at the ASCO...
06/14/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
Use of Homologous Recombination Thresholds for Forecasting Response to Platinum-Based Treatment in Triple-Negative Breast Cancer
06/14/2022

Ellen Kurek

Ellen Kurek
Researchers at ASCO conducted an exploratory analysis evaluating the ability of GIS thresholds of 33 or greater, and 42 or greater to predict response to platinum-based treatment in patients with triple-negative breast cancer.
Researchers at ASCO conducted an exploratory analysis evaluating the ability of GIS thresholds of 33 or greater, and 42 or greater to predict response to platinum-based treatment in patients with triple-negative breast cancer.
Researchers at ASCO conducted an...
06/14/2022
Journal of Clinical Pathways
Conference Coverage
BRCA Variants in Patients With Ovarian Cancer and the Risk of Adverse Reactions
06/10/2022

Marta Rybczynski

Marta Rybczynski
A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.
A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.
A real-world study presented at...
06/10/2022
Journal of Clinical Pathways
Conference Coverage
Treatment Patterns and Efficacy of Bruton Tyrosine Kinase Inhibitors in Patients With MCL
06/09/2022

Robert Fee

Robert Fee
Retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network assessed treatment patterns and associated outcomes in patients with MCL who were treated with BTKi.
Retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network assessed treatment patterns and associated outcomes in patients with MCL who were treated with BTKi.
Retrospective multicenter chart...
06/09/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
Bringing the Benefits of At-home Programs to Patients With Cancer Who Live in Rural Areas
06/09/2022

Robert Fee

Robert Fee
Researchers show how patients with cancer who are living in rural communities can receive the benefits of oncology hospital at home programs in a case study from the 2022 ASCO Annual Meeting.
Researchers show how patients with cancer who are living in rural communities can receive the benefits of oncology hospital at home programs in a case study from the 2022 ASCO Annual Meeting.
Researchers show how patients...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Study Examines Charges Associated With US Hospital Payer-Specific Negotiated Mammography
06/09/2022

Robert Fee

Robert Fee
A cross-sectional study of US acute care and critical access hospitals presented at the 2022 ASCO Annual Meeting examined the factors associated with payer-negotiated mammography charges.
A cross-sectional study of US acute care and critical access hospitals presented at the 2022 ASCO Annual Meeting examined the factors associated with payer-negotiated mammography charges.
A cross-sectional study of US...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Case Study Assesses Self-Reported Financial Difficulties Among Patients With Multiple Myeloma or Chronic Lymphocytic Leukemia
06/09/2022

Robert Fee

Robert Fee
A study presented by the Alliance for Clinical Trials in Oncology at the 2022 ASCO Annual Meeting confirms that many patients with blood cancers experience financial difficulties.
A study presented by the Alliance for Clinical Trials in Oncology at the 2022 ASCO Annual Meeting confirms that many patients with blood cancers experience financial difficulties.
A study presented by the...
06/09/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
Factors Predicting the Likelihood of Undergoing Biomarker Testing in Ovarian Cancer
06/08/2022

Marta Rybczynski

Marta Rybczynski
According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.
According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.
According to findings presented...
06/08/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use